Scholarlink

<p>Concurrent cervical-vaginal high-grade squamous intraepithelial lesion (HSIL) is increasingly prevalent with carcinogenic potential. For gynecologic oncologists, non-invasive, organ-preserving treatment of this condition remains a challenge. While Hiporfin-photodynamic therapy (PDT) has proven effective for cervical HSIL or vaginal HSIL alone, its efficacy in concurrent cervical-vaginal HSIL remains unreported. We treated 8 pathologically confirmed patients with Hiporfin-PDT: 2.0&#xa0;mg/kg intravenous Hiporfin followed by 630-nm red laser irradiation 48–72&#xa0;h later, with one session per patient initially. At 3–6 months, the complete response (CR) rate was 75.0% (6/8); the 2 partial response (PR) patients achieved CR after a second PDT session or two sessions of thermocoagulation. Our preliminary findings suggest that Hiporfin-PDT has potential feasibility as a non-invasive option for concurrent cervical-vaginal HSIL, warranting further investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Systematic photodynamic therapy for concurrent cervical-vaginal high-grade squamous intraepithelial lesion: a series of eight cases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月27日

查看全文
  • Yu Liu,
  • Ruifang Wu,
  • Changzhong Li,
  • Ruizhen Li

摘要

Concurrent cervical-vaginal high-grade squamous intraepithelial lesion (HSIL) is increasingly prevalent with carcinogenic potential. For gynecologic oncologists, non-invasive, organ-preserving treatment of this condition remains a challenge. While Hiporfin-photodynamic therapy (PDT) has proven effective for cervical HSIL or vaginal HSIL alone, its efficacy in concurrent cervical-vaginal HSIL remains unreported. We treated 8 pathologically confirmed patients with Hiporfin-PDT: 2.0 mg/kg intravenous Hiporfin followed by 630-nm red laser irradiation 48–72 h later, with one session per patient initially. At 3–6 months, the complete response (CR) rate was 75.0% (6/8); the 2 partial response (PR) patients achieved CR after a second PDT session or two sessions of thermocoagulation. Our preliminary findings suggest that Hiporfin-PDT has potential feasibility as a non-invasive option for concurrent cervical-vaginal HSIL, warranting further investigation.